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1. Introduction 
The number of cases in which hemodialysis therapy for diabetic nephropathy is required 
has been increasing. Currently, the goal of treatment for renal fibrosis is not only to prevent 
the development and progression of the disease, but also to promote its remission and 
regression. 
It is well known that glomerulosclerosis and tubulointerstitial fibrosis occur during the 
early stages of diabetic nephropathy. It has been demonstrated that the development of 
tubulointerstitial lesions is more closely correlated with a progressive decline in renal 
function compared to glomerular lesions (Bohle et al., 1991). Tubulointerstitial fibrosis 
ultimately leads to renal failure as a result of renal atrophy. The myofibroblasts emerging 
in tubulointerstitial fibrosis tissue have been indicated to play a crucial role in the 
development and progression of fibrosis (Simonson, 2007). They overproduce 
extracellular matrix (ECM) molecules, including type I collagen and fibronectin, and 
repress ECM degradation through the production of tissue inhibitor of metalloproteinase-
1 (TIMP-1) (Edwards et al., 1987) and plasminogen activator inhibitor-1 (PAI-1) in 
response to transforming growth factor-ǃ1 (TGF-ǃ1), which is increased in DN (Laiho et 
al., 1987), followed by ECM accumulation (i.e. fibrosis). Furthermore, the myofibroblasts 
may induce fibrosis tissue contraction via increased cell contraction promoted by ǂ-
smooth muscle actin (ǂ-SMA) expression, leading to renal atrophy and failure. 
Myofibroblasts are considered to be derived from various kinds of cells, e.g. fibroblasts 
(Strutz and Zeisberg, 2006), epithelial cells (Iwano et al., 2002), endothelial cells (Zeisberg 
et al., 2008), pericytes (Humphreys et al., 2010), and bone marrow-originated cells (Keeley 
et al., 2010), via stimulation by TGF-ǃ1. 
Although ǂ-SMA expression, which is the most pronounced characteristic of myofibroblasts, 
has been considered to cause tissue contraction, the detailed mechanism has not yet been 
determined. Myofiboblasts were first described in wound-healing granulation tissue 
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(Gabbiani et al., 1971), where they were referred to as “modified fibroblasts” on the basis of 
their ultrastructural identification in transmission electron microscopic studies. These cells 
include a fibrillar system corresponding to stress fibers, nuclear indentation implying cell 
contraction, and cell-to-ECM and cell-to-cell junctions. Thus, modified fibroblasts 
(myofibroblasts) were described as an intermediate type of cell between fibroblasts and 
smooth muscle cells due to their ability to produce ECM and contract. Later investigators 
have noted that ǂ-SMA expression in the stress fibers was the major characteristic of 
myofibroblasts.  
At present, cells with ǂ-SMA-positive stress fibers in the interstitium, except for vascular 
components, are recognized to be myofibroblasts. In vertebrate tissues, six actin isoforms 
have been identified. Four actin isoforms, including the ǂ-skeletal, ǂ-cardiac, ǂ-vascular and 
Ǆ-enteric isoforms, are tissue-restricted and involved in cell contraction. The other two actin 
isoforms, the ǃ-cytoplasmic and Ǆ-cytoplasmic isoforms, are ubiquitously expressed. These 
have been considered to constitute noncontractile cytoskeletons. The ǂ-vascular actin is the 
SMA isoform, referred to as “ǂ-SMA”. During myofibroblast transdifferentiation, the actin 
isoform transitions, at least in part, from the cytosolic actin to ǂ-SMA. It has been proposed 
that myofibroblasts have the ability to contract due to their expression of ǂ-SMA. 
Fibronectin, a 440 kDa dimeric glycoprotein, is one of the ECM molecules that exerts various 
functions, including adhesion, migration and differentiation. The fibronectin subunit is 
composed of three internally homologous repeats and contains binding sites for cell surface 
receptors and for other ECM components (Magnusson & Mosher, 1998; Peterson et al., 
1983). Fibronectin polymorphisms arise from the alternative splicing of mRNA at three 
regions, ED-A, ED-B and IIICS (Norton & Hynes, 1987) (Fig. 1). The two former sequences 
are either omitted or included, while the latter one varies in length. Fibronectins are 
present in an insoluble form in the ECM, and in a soluble form in circulation, namely as 
cellular fibronectin and plasma fibronectin. Only cellular fibronectin contains ED-A and ED-
B (Vartio et al., 1987). The fibronectin ED-A and fibronectin ED-B isoforms are 
predominantly expressed in embryonic tissue, and are seldom found in normal adult 
tissues. However, fibronectin ED-A has been demonstrated to be re-expressed in a variety of 
reactive and pathological processes, such as wound healing (Ffrench-Constant et al., 1989), 
arterial internal thickening (Glukhova et al., 1989) and liver fibrosis (Jamagin et al., 1994). In 
vitro, TGF-ǃ1 has been shown to increase fibronectin production, and it regulates the splicing 
pattern of fibronectin pre-messenger RNA, followed by expression of the ED-A domain 
(Balza et al., 1988; Borsi et al., 1990). Moreover, it has been suggested that the fibronectin 
ED-A isoform modulates various cells to generate myofibroblasts which express ǂ-SMA 
(Bochaton-Piallat et al., 2000; Ffrench-Constant et al., 1989; Jamagin et al., 1994). Gabbiani 
and coworkers demonstrated that the fibronectin ED-A isoform plays a crucial role in TGF-
ǃ1-induced myofibroblast transdifferentiation in an in vitro study using human 
subcutaneous fibroblasts (Serini et al., 1998). 
In the present study, we examined whether TGF-ǃ1 induces the expression of the ED-A 
domain in fibronectin, and whether this, in turn, leads to ǂ-SMA expression in renal 
fibroblasts by using an in vitro model of fibrosis due to diabetic nephropathy. Furthermore, 
whether the fibronectin ED-A isoform stimulates the contraction of the collagen gel through 
the expression of ǂ-SMA and the accumulation of type I collagen was examined. 
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Fig. 1. The molecular structure of fibronectin ED-A and ED-B.  
The fibronectin subunit is composed of three different repeating sequences: type I 
(rectangles), type II (ovals) and type III (circles). Sets of repeats constitute binding domains 
for fibrin, fibronectin (FN), collagen, cells and heparin as described. Sequence variations can 
occur in all three points of the fibronectin subunit: extra domains A and B (ED-A and ED-B, 
respectively) and the IIICS (Wierzbicka-Patynowski & Schwarzbauer, 2003). Allows indicate 
approximate intron positions determined in the murine gene. 
2. Materials and methods 
2.1 Materials   
Porcine type I collagen solution was purchased from Nitta Gelatin (Osaka, Japan), 
recombinant human TGF-ǃ1 was purchased from R and D Systems (MN, USA), and the 
mouse monoclonal antibodies against ǂ-SMA and ED-A were obtained from Sigma-Aldrich 
(MO, USA) and Abcam (Cambridge, UK), respectively. The fluorescein isothiocyanate 
(FITC)-conjugated goat anti-mouse IgG secondary antibody against these monoclonal 
antibodies was purchased from Caltag Laboratories (CA, USA). Rat type I collagen ELISA 
kits were obtained from Cusabio (Wuhan, China). 
2.2 Cell culture 
Normal rat kidney fibroblasts (NRK 49F cells) were obtained from the RIKEN Cell Bank 
(Tsukuba, Japan). The cells were maintained in Dulbecco’s minimal essential medium (D-
MEM) (Nissui Pharmaceutical, Tokyo, Japan) containing 100 IU ml-1 penicillin, 100 μg ml-1 
streptomycin, and 10% fetal bovine serum (FBS) (JRH Biosciences, KS) at 37°C in a 
humidified, 5% CO2 atmosphere. FBS had been heat-inactivated at 56°C for 30 min prior to 
use. Cells from passage 3 to passage 8 were used in the experiments described below. 
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Monolayer cultures of 2 X 104 cells ml-1 were grown on two-well Labtek Chamber Slides (AS 
ONE, Osaka, Japan). The cell cultures were divided into 4 groups: a control group, cultured 
with 0.5% FBS; a TGF-ǃ1 group, cultured with 0.5% FBS + 5 ng ml-1 TGF-ǃ1; an anti-ED-A 
antibody group, cultured with 0.5% FBS + 5 ng ml-1 TGF-ǃ1 + 10 μg ml-1 anti-ED-A antibody; 
an IgG group, cultured with 0.5%FBS + 5ng ml-1 TGF-ǃ1 + 10 μg ml-1 mouse IgG (negative 
control, R &D Systems, Inc., MN, USA). Furthermore, each group was sub-divided into two 
groups: the 1D (1 day) group, which was cultured for 24h after the initiation of culture; the 
2D (2 day) group, which was cultured for 24h after refeeding the cells the same medium 24 
h after culture initiation. The cells and the supernatants of all groups were subjected to 
immunofluorescence studies for fibronectin ED-A or ǂ-SMA, and to an ELISA for type I 
collagen, respectively.   
2.3 Immunofluorescence microscopy for fibronectin ED-A and α-SMA 
The cells from monolayer cultures were fixed in 4% paraformaldehyde in 0.1 M phosphate-
buffered saline (pH 7.4) for 10 min. After rinsing, the cells were permeabilized with 0.5% 
Triton X-100 for 20 min in order to identify ǂ-SMA in the cells, this process was omitted in 
studies for detecting fibronectin ED-A. After washing, the cells were incubated with the 
primary antibody against ǂ-SMA or fibronectin ED-A for 2 h at room temperature. After 
being rinsed, they were incubated with FITC-conjugated goat anti-mouse IgG secondary 
antibody for 1 h at room temperature. After staining, the cells were rinsed, observed and 
photographed using an Olympus BX 60 microscope equipped with epifluorescence optics. 
The assessment of the percentage of cells with ǂ-SMA-positive stress fibers was performed 
as follows: when there were one or more stress fibers with ǂ-SMA-positive staining in a cell, 
the cell was considered to be ǂ-SMA-positive and was referred to as a “myofibroblast”. The 
percentage of myofibroblasts was represented by counting the ǂ-SMA-positive cells among 
100 to 500 cells. 
2.4 Gel contraction assay 
A total of 7 ml of a collagen solution (3 mg/ml stock) was gently mixed with 2 ml of 5-fold-
concentrated D-MEM on ice. The mixture was adjusted to pH 7.4 with 1 ml of 200 mM 
HEPES plus 2.2% NaHCO3 in distilled water. This collagen mixture (0.3ml) was added to 
each well of a 24 well plate (Becton-Dickinson Labware, NJ). Then, the collagen gel was 
formed by the incubation of the mixture for 30 min at 37°C. After gelatinization, an NRK 
49F cell suspension (2 X104 cells ml-1) was poured on the gel in each well. Preincubation of 
the cell-populated collagen lattice was performed in D-MEM + 10% FBS for 24 h. Next, the 
gels were rinsed with serum-free D-MEM three times for 30 min. Then, the gel cultures were 
divided into 4 groups similar to the immunofluorescence studies: a control group, cultured 
in 0.5% FBS; a TGF-ǃ1 group, cultured in 0.5% FBS + 5 ng ml-1 TGF-ǃ1; an anti-ED-A 
antibody group, cultured in 0.5% FBS +5 ng ml-1 TGF-ǃ1+ 10 μg ml-1 anti-ED-A antibody and 
an IgG group, cultured in 0.5%FBS + 5ng ml-1 TGF-ǃ1 + 10 μg ml-1 mouse IgG. The gels were 
then detached from the lateral wall and bottom of each well with a microspatula and 
cultured for 48 h. After 48 h in culture, the diameter of each gel was measured with a ruler 
to assess the gel contraction after treatment with the reagents. In addition, to confirm that 
the shrinkage of the cell-populated collagen lattice occurred due to gel contraction, rather 
than gel digestion, another study was performed. For this study, after gelatinization, the 
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NRK49F cell suspension (5000 cells per 5μl) was placed in a very small area near the margin 
of the gel, and incubated for 1h at 37°C. Then, preincubation was done as above. After 
rinsing, the gels were cultured in the control medium and the medium with 5ng ml-1 TGF-ǃ1 
for 48h at 37°C following gel detachment. After 48h, the shapes of the gels were observed. 
2.5 Enzyme-linked immunosolvent assay for type I collagen accumulation in the 
supernatants of the cultures 
The supernatants from monolayer cultures were added to the wells of 96 well plate, which 
were pre-coated with a mouse monoclonal antibody against rat type I collagen, and were 
incubated for 2 h at 37°C. After removing the liquid from each well, a biotin-conjugated 
anti-mouse IgG secondary antibody solution was added, and cells were incubated for 1 h at 
37°C. After rinsing, each well was exposed to the horseradish peroxidase-avidin solution for 
1 h at 37°C. After washing, the TMB substrate was added, and cells were incubated for 20 
min at 37°C. Then, the stop solution was added to each well, while the optical density of 
each well was determined using a microplate reader, the Multiskan GO (Thermo Fisher 
Scientific, Yokohama, Japan), at 450 nm. The value of the optical density was converted to 
the type I collagen concentration in the supernatant of the monolayer culture. 
2.6 Statistical analysis 
The experimental data are presented as the means ±SD. The statistical analyses were 
performed using Student’s t-test. Differences were considered to be statistically significant 
at P<0.05. 
3. Results 
3.1 TGF-β1- induced the expression of ED-A and α-SMA 
ED-A expression was induced in a dot or short linear pattern on the cell surface by TGF-ǃ1 by 
24 h after initiation of culture (the 1D・TGF-ǃ1 group), and was further increased after the 48 h 
culture (the 2D・TGF-ǃ1 group) (Figs. 2c, 2d). On the other hand, the expression of 
intracellular ǂ-SMA was not observed 24 h after the initiation of culture (the 1D・TGF-ǃ1 
group), but was induced in stress fiber formations after 48 h in culture (the 2D・TGF-ǃ1 group) 
(Figs. 2g, 2h). The expression of ED-A and ǂ-SMA was not observed in the cells cultured in the 
medium without TGF-ǃ1 (the 1D and 2D  control groups) (Figs. 2a, 2b, 2e, 2f). 
3.2 The effects of the anti-ED-A antibody on TGF-β1- induced α-SMA expression 
The TGF-ǃ1- induced ǂ-SMA expression was markedly decreased by adding an anti-ED-A 
antibody to the medium (Fig. 3A). The rates of ǂ-SMA-positive cells in stress fiber 
formations were as follows: the 2D control group (0%), the 2D TGF-ǃ1 group (97%), the 2D 
anti-ED-A antibody group (36%), and the 2D IgG group (95%) (Fig. 3B). 
3.3 The characteristics of TGF-β1-induced gel shrinkage 
When the cells were ubiquitously poured on the gel, TGF-ǃ1-induced gel shrinkage occurred 
in the shape of a circle after culture for 48h (Fig. 4Aa). The diameters of gels were 99.4±1.0%  
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Fig. 2. Immunofluorescent staining for ED-A and ǂ-SMA induced by TGF-ǃ1. 
a, c, e, g, ID groups; b, d, f, h, 2D groups; a, b, c, d, Immunostaining for ED-A; e, f, g, h, 
Immunostaining for ǂ-SMA; a, b, e, f, control groups; c, d, g, h, TGF-ǃ1 groups. a, No 
immunostaining. b, No immunostaining. c, Immunostaining for ED-A is shown by the dot 
or short linear pattern on the cell surface. d, Immunostaining for ED-A was increased. e, No 
immunostaining. f, No immunostaining, g, No immunostaining. h, Immunostaining for ǂ-
SMA is seen in the stress fiber formation in the cells. Bar, 10 μm. 
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in the control medium group and 86.4±1.7% in the TGF-ǃ1 group (p<0.001) (Fig. 4Ab). On 
the other hand, when the cells were placed in a small region close to the margin of the gel, 
the gel exhibited indentation toward the cell mass in response to TGF-ǃ1 (Fig. 4B). If gel 
shrinkage occurs due to gel digestion, the gel would reveal the features of digestion, such as 
the dissolution of the gel around the cell mass, and would form a thin layer or disappear. 
However, because the present study did not show these features, gel digestion was not 
considered to be responsible for the observed gel shrinkage. The observed indentation was 
thought to be caused by retraction of the gel resulting from cell contraction. 
3.4 The effects of the anti-ED-A antibody on TGF-β1-induced gel contraction 
Gel contraction did not occur in the control medium throughout the experimental period. In 
addition, no gel contraction was observed in any of the 1D groups. In the 2D groups, TGF-ǃ1 
remarkably evoked gel contraction. The treatment with the anti-ED-A antibody was shown 
to repress TGF-ǃ1-induced gel contraction. The diameters of the gels in the four groups were 
as follows: the 2D control group (100%), the 2D TGF-ǃ1 group (84.0±1.9%), the 2D anti-ED-A 
antibody group (89.5±1.9%, p<0.05 vs the 2D TGF-ǃ1 group),  and the 2D IgG group 
(83.7±1.6%, p<0.05 vs the 2D anti-ED-A antibody group) (Fig. 5). 
3.5 The effects of the anti-ED-A antibody on TGF-β1-stimulated type I collagen 
accumulation in the supernatants of the cell cultures 
There were no significant differences in the accumulation of type I collagen in the cell 
supernatants between the three 1D groups (the control group, 1420±200; the TGF-ǃ1 group, 
1470±100; the anti-ED-A antibody group, 1510±160 ; the IgG group, 1513±26 pg ml-1). In the 
2D groups, the accumulation of type I collagen in the supernatant of the TGF-ǃ1 group was 
increased. The increased accumulation of collagen was repressed by addition of the anti-ED-
A antibody to the medium with TGF-ǃ1 (Fig. 5). The concentrations of the supernatants in 
the four 2D groups (control, TGF-ǃ1, anti-ED-A antibody, IgG) were 1980±220, 2730±110, 
2490±18, 2570±3 pg ml-1, respectively (p<0.001, the control group vs the TGF-ǃ1 group; 
p<0.05, the TGF-ǃ1 group and the IgG group vs the anti-ED-A antibody group) (Fig. 6). 
4. Discussion 
Myofibroblasts expressing ǂ-SMA have been shown to emerge in fibrotic diseases (Tomasek 
et al., 2002). In general, ǂ-SMA is considered to be profoundly involved in the progression of 
fibrosis, but the detailed significance of ǂ-SMA expression remains unresolved. For example, 
it is unclear whether myofibroblasts are really essential for fibrosis. In contrast to general 
considerations, there have been some reports indicating that myofibroblasts are not 
necessary for the progression of fibrosis. For example, Takeji et al. suggested that ǂ-SMA 
expression provided benefits for fibrosis (Takeji et al., 2006). It was demonstrated that 
defects in ǂ-SMA enhanced the progression of fibrosis by performing unilateral ureteral 
obstruction in a renal interstitial fibrosis model in an ǂ-SMA knockout mouse. Furthermore, 
transfection of the ǂ-SMA gene into ǂ-SMA-/- myofibroblasts from these mice suppressed 
fibrosis. These results indicated that ǂ-SMA expression suppresses, rather than accelerates, 
fibrosis. The ǂ-SMA-/- myofibroblasts that were obtained possessed the ability to migrate, 
proliferate, and overproduced type I collagen. These cells did not express ǂ-SMA, but did 
start to overexpress skeletal muscle ǂ-actin, smooth muscle Ǆ-actin, and related molecules. 
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These cells also overproduced type I collagen compared to conventional myofibroblasts 
expressing ǂ-SMA. Because the cells which were established by transfection of the ǂ-SMA 
gene into the ǂ-SMA-/- cells failed to produce type I collagen, these cells might resemble 
smooth muscle cells. It is likely that myofibroblasts are an intermediate type of cells between 
ǂ-SMA-/- cells and smooth muscle cells, given their ability to express ǂ-SMA and produce 
type I collagen. Taken together, their report does not refute the generally accepted concept  
 
Fig. 3. Immunofluorescent staining for ǂ-SMA was influenced by the anti-ED-A antibody 
Aa, the 2D TGF-ǃ1 group; b, the 2D anti-ED-A antibody group; c, the 2D IgG group; B, 
Counts of cells immunostained for ǂ-SMA in the stress fiber formation. Aa and Ac, 
Immunostaining for ǂ-SMA was shown in the stress fiber formation. Ab, Cells expressing 
ǂ-SMA in the stress fiber formation were markedy decreased in number. Immunostaining 
for ED-A was seen in response to addition of the anti-ED-A antibody to the medium. B. 
Cells with ǂ-SMA expression induced by TGF-ǃ1 were decreased in number in the anti-ED-
A antibody group. Bar, 10 μm. 
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Fig. 4. Morphological alterations of gels in response to TGF-ǃ1 according to differences in the 
pouring methods.  
A. Ubiquitous pouring of cells. a. The shape of the gel b. the diameters of the gels. B. Spot 
pouring of cells. Aa. The change in shape induced by TGF-ǃ1 is indicated by the circle. Ab. 
TGF-ǃ1 significantly induced gel shrinkage. The data represent the diameters of the gels 
compared to the well. B. The gel was deformed, as shown by the indentation torward the 
cell mass (arrows).  
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Fig. 5. Type I collagen gel contraction. 
No gel contraction occurred in any of the 1D groups. TGF-ǃ1 was shown to evoke gel 
contraction in the 2D TGF-ǃ1 and IgG groups. TGF-ǃ1 -induced gel contraction was 
attenuated by adding the anti-ED-A antibody. The data represent the diameters of the gels 
compared to the well. 
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Fig. 6. Type I collagen accumulated in the supernatants of the monolayer cultures. 
The TGF-ǃ1 and anti-ED-A antibodies do not influence the type I collagen accumulation in 
1D groups. TGF-ǃ1 increased the type I collagen accumulation in the 2D TGF-ǃ1 and IgG 
groups. The TGF-ǃ1- accelerated collagen accumulation was repressed by the anti-ED-A 
antibody.  
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that ǂ-SMA contributes to the progression of fibrosis, but do add an additional role for ǂ-
SMA producing cells. There was another report (Leemans et al., 2009) that suggested that 
renal fibrogenesis persists despite decreasing numbers of ǂ-SMA+ myofibroblasts. This also 
does not contradict the general consensus about the role of myofibroblasts, because it can be 
considered that after myofibroblasts induce the accumulation of collagen fibrils by forming 
rigid fibrils which are resistant to proteolysis by proteinases, they undergo apoptosis. 
Subsequently, the ǂ-SMA- fibroblasts might add collagen fibers to these rigid fibers. In this 
case, myofibroblasts would make up the nucleus of the accumulated collagen fibrils. 
In the present study, TGF-ǃ1 induced the production of fibronectin ED-A, which was 
anchored to kidney fibroblasts, and subsequently induced ǂ-SMA expression in the stress 
fiber formations in cells. Stress fiber formation is involved in cell contraction, which results 
in gel contraction via the consecutive binding of ǂ-SMA, focal adhesion, integrins, and type I 
collagen. In addition, the ǂ-SMA expression was strongly inhibited by exposing the cells to 
an anti-ED-A antibody. Therefore, the TGF-ǃ1 -induced expression of ǂ-SMA was 
considered to be, at least to a large extent, dependent on ED-A expression. This is 
compatible with the fact that the fibronectin ED-A isoform contributes to the 
transdifferentiation of a variety of cells into myofibroblasts with ǂ-SMA (Bochaton-Piallat et 
al., 2000; Ffrench-Constant et al., 1989; Jamagin et al., 1994).  
It was shown in the renal fibroblasts that the intracellular signaling pathways of TGF-ǃ1-
induced fibronectin ED-A expression involves Smad 3 (Bondi et al., 2010). The pathways 
leading to ǂ-SMA expression and myofibroblast transdifferentiation differed between 
reports. Our previous report suggested that the pathway of TGF-ǃ1-induced ǂ-SMA 
expression involved p38 MAPK (Ina et al., 2011). This finding is consistent with a study by 
Miura et al. (Miura et al., 2006), in which retinal pigment epithelial cells were used. On the 
other hand, Masszi et al. (Masszi et al., 2003) have found that the activation of the Rho 
kinase pathway was involved in the ǂ-SMA expression in renal tubular epithelial cells. The 
contrast between these findings might be due to the differences in the cells used. How ED-A 
expression activated the p38 MAPK pathway in the present study remains to be determined. 
However, ED-A has been identified as an endogenous ligand for Toll-like receptor-4 
(Gondokaryono et al., 2007; Lefebvre et al., 2011; Ricupero et al., 2001) which is well known 
to be expressed in inflammatory cells such as macrophages, mast cells, and leukocytes, and 
is associated with innate immunity. Recently, it was demonstrated that Toll-like receptor 4 is 
also expressed in renal interstitial fibroblasts (Sorensen et al., 2011). Furthermore, the 
activation of Toll-like receptor 4 was reported to promote renal tubulointerstitial fibrosis 
(Campbell et al., 2011; Sorensen et al., 2011). It is therefore possible that ED-A binds to Toll-
like receptor 4 and activates it, leading to stimulation of the related signaling pathways, 
eventually promoting the signaling by TGF-ǃ1 and stimulating ǂ-SMA expression.  
Because the immunostaining for fibronectin ED-A was positive in both conventional 
immunocytochemistry and in that without the first antibody (the anti-ED-A antibody) of the 
cells exposed to the antibody in culture, the epitope appears to be present in a region other 
than the receptor-binding site. In this case, the binding of the antibody to the epitope might 
cause alterations in the conformation of the receptor binding site, and inhibit the binding of 
ED-A to the receptor. In the current study, since contraction of the NRK49F cell-populated 
collagen lattice was suppressed by the adding anti-ED-A antibody, the ED-A expression was 
considered to be involved in TGF-ǃ1-induced gel contraction.  
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Fig. 7. The hypothesis: about the contribution of fibronectin ED-A expression to ǂ-SMA 
expression and type I collagen accumulation. 
We hypothesize the mechanism ad follows: TGF-ǃ1 induces ED-A domain expression 
through the pathway involving Smad 3 in the fibronectin molecule. The fibronectin ED-A is 
anchored to the cell via a combination of the cell-binding domain and the integrin on the 
cell. Subsequently, the ED-A domain binds to the receptor (the Toll-like receptor) and 
stimulates it. Furthermore, the signaling transfers to one of the TGF-ǃ1-activated pathways, 
which may be the p38 MAPK pathway. Finally, the ED-A-stimulated pathway induces ǂ-
SMA expression and type I collagen accumulation, which involves the increased synthesis 
of collagen and decreased degradation of collagen via the production of proteinase 
inhibitors, TIMPs and PAI-1. 
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The previous study demonstrated that TGF-ǃ1 caused the contraction of the fibroblast 
(without ǂ-SMA expression)-populated collagen lattice in culture medium with 10% FBS. 
The TGF-ǃ1-induced gel contraction was accelerated by expressing ǂ-SMA, which was 
induced by a low concentration of FBS and the addition of TGF-ǃ1 (Ina et al., 2011). 
Therefore, TGF-ǃ1 was suggested to exert distinct functions on ǂ-SMA expression and gel 
contraction. In addition, it was shown that TGF-ǃ1-induced gel contraction occurred via the 
p38 MAPK pathway and the Rho kinase pathway (Ina et al., 2011). Taken together, since the 
p38 MARK pathway is involved in both ǂ-SMA expression and gel contraction, it is likely 
that ED-A expression might stimulate the p38 MAPK pathway activated by TGF-ǃ1, 
followed by myofibroblast transdifferentiation and gel contraction.  
These findings still have not clarified what gel contraction means in the fibrosis of diabetic 
nephropathy. We believe that it corresponds to the renal atrophy following fibrosis. 
However, it is also possible that gel contraction might reflect the shrinkage of collagen 
fibrils, allowing collagen molecules to become nearer to each other, followed by increased 
crosslinking, which leads to the formation of rigid fibrils. These are resistant to proteolysis 
by proteinases, thus leading to the accumulation of fibrils, and therefore, fibrosis. 
In the present study, we also demonstrated that accumulation of type I collagen was, at 
least in part, dependent on ED-A expression. To our knowledge, this is the first report 
that ED-A mediates TGF-ǃ1-stimulated type I collagen accumulation, while there was a 
previous report that ED-A stimulated type I collagen mRNA expression (Serini et al., 
1998). There are both Smad-dependent and independent pathways, including the p38 
MAPK pathway, via which TGF-ǃ1 can stimulate the production of ECM containing type I 
collagen (Eickelberg, 2001). The observed ǂ-SMA expression, gel contraction, and type I 
collagen accumulation are, at least in part, dependent on ED-A expression. The ǂ-SMA 
expression was the most dependent of these events on ED-A. We therefore hypothesized 
that ǂ-SMA expression is, to a large extent, dependent on ED-A expression via the p38 
MAPK pathway. On the other hand, gel contraction and type I collagen accumulation 
were, to a lesser extent, dependent on ED-A expression, because they are comparatively 
mediated by pathways other than the p38 MAPK pathway. ED-A binds to Toll-like 
receptor-4 and activates it, followed by signaling via diverse pathways in inflammatory 
cells (Akira & Takeda, 2004). The p38 MAPK pathway is also included in these pathways. 
Thus, it is most likely that the ǂ-SMA expression, gel contraction, and type I collagen 
accumulation induced by ED-A expression are mediated by activating the p38 MAPK 
pathway (Fig. 6). In other words, ED-A appears to enhance the activity of the p38 MARK 
pathway stimulated by TGF-ǃ1. 
5. Conclusion 
The TGF-ǃ1-induced ǂ-SMA expression, followed by gel contraction and stimulated type I 
collagen accumulation, were, at least in part, dependent on fibronectin ED-A expression. 
These findings suggest that tubulointerstitial fibrosis associated with diabetic 
nephropathy and fibrotic tissue contraction leading to renal atrophy are partly mediated 
by TGF-ǃ1-induced fibronectin ED-A expression. In addition, since the fibronectin ED-A 
isoform is seldom found in normal adult subjects, the negative effects induced by 
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inhibition of ED-A expression or activity would likely be minimal. Taken together, our 
findings and those of previous studies suggest that ED-A may be a target for treatment of 
diabetic nephropathy. 
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